卵巢癌FIGO III-IV期诊断性腹腔镜与肿瘤细胞减灭术:一期与两期序贯对生存的影响
这项回顾性多中心研究基于FRANCOGYN数据库,纳入208例FIGO III-IV期卵巢肿瘤患者,比较一期手术与两期序贯手术对生存的影响。
要点
- 在细胞减灭术同期行探查性腹腔镜未显著改善FIGO III-IV期卵巢癌的无复发生存。
核心结论
- 在细胞减灭术同期行探查性腹腔镜未显著改善FIGO III-IV期卵巢癌患者的无复发生存,总生存分析也观察到这一趋势。
研究设计与样本
- 回顾性多中心研究,基于FRANCOGYN组数据库,纳入208例FIGO III-IV期卵巢肿瘤接受手术治疗的患者。
- 分为两组:第一组接受一期单次手术的初始手术治疗,第二组接受两期序贯的初始手术治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This is a retrospective study designed to assess the impact of two-stage versus single-stage surgical management on survival in patients with FIGO III-IV ovarian neoplasia receiving surgical management. METHODS: This is a retrospective, multicenter study, based on the FRANCOGYN group database. Two groups were studied, the first having primary surgical management in a single operation, and the second having two-stage sequence primary surgical management. RESULTS: 208 patients were included in the study. In terms of overall survival, in univariate analysis, there was a statistically significant difference in favor of single-stage surgical management, but this was not demonstrated in multivariate analysis (p = 0,228). Similarly, in terms of recurrence-free survival, there was no statistically significant difference between the two groups studied (p = 0,123). CONCLUSION: Performing exploratory laparoscopy at the same time as cytoreduction surgery does not significantly improve recurrence-free survival in patients with FIGO III-IV ovarian cancer. This trend was also observed in the overall survival analysis.
引用
- Rebouillat C, Pomel C, Bourdel N, et al. Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequence. Gynecol Oncol. 2025. PMID: 40896861. doi:10.1016/j.ygyno.2025.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。